Incyte unveils positive results from Phase 2 ruxolitinib cream study
Category: #health  By Pankaj Singh  Date: 2019-10-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Incyte unveils positive results from Phase 2 ruxolitinib cream study

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continuously working towards finding a better treatment to cure this skin disease.

Incyte Corporation, a US based pharmaceutical firm headquartered in Delaware, reportedly announced the positive 52-week results from the company’s dose-ranging, double-blind and randomized, Phase 2 clinical trial evaluating ruxolitinib cream, an anti-inflammatory, nonsteroidal, JAK inhibitor treatment, in adults with vitiligo.

As announced by the firm earlier, the trial met its primary endpoint, showcasing that significantly more patients who were treated with ruxolitinib over a span of 24 weeks attained an improvement of ≥50% from baseline results in the F-VASI50 (facial vitiligo area severity index) score in comparison with the patients who were treated with a non-medicated cream. 

New results seen at week 52 demonstrate significant improvements in full body repigmentation when treated with ruxolitinib cream, calculated by the patient proportion achieving more than or equal to 50% improvement from the baseline in the total T-VASI50 (vitiligo area severity index), a vital secondary endpoint.     

Additionally, after the 52 week-long therapy with 1.5% ruxolitinib cream administered twice daily, 51% patients obtained a greater than or equal to 75% improvement (F-VASI75) and 58% patients achieved F-VASI50. After approximately 24 weeks, F-VASI75 is the primary measure of outcome of both TRuE-V2 and TRuE-V1 randomized Phase 3 clinical trials that are already under progress.

Group Vice President, Inflammation & Autoimmunity at Incyte, Jim Lee, M.D. stated that the company is very encouraged seeing the new positive data showcased at EADV, which demonstrates significant facial as well as total body repigmentation of the vitiligo lesions in patients who were treated by ruxolitinib cream, and continued enhancements with a treatment of longer duration.

Lee added that as the company seeks to provide a highly-needed option for the patients affected by this life changing disease, it is thrilled that pivotal Phase 3 trials which are evaluating ruxolitinib cream in patients with vitiligo are under progress, with their results predicted to be released in 2021.    

 

 

 

 

 

 

 

 

Source credit : https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-52-week-results-randomized-phase-2



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...